Carol Zhao

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension

Raymond L. Benza, Manreet Kanwar, Amresh Raina et al. · CHEST Journal · 2020 · 288 citations · Full text

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Edith A. Perez, Ahmad Awada, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2015 · 88 citations

Advanced Breast Cancer, Medicine, Cancer Management +10

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

Ahmad Awada, Agustin A. García, Stephen L. Chan et al. · The Lancet Oncology · 2013 · 82 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +10

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension

Robert P. Frantz, Harrison W. Farber, David B. Badesch et al. · CHEST Journal · 2018 · 57 citations · Full text

Hypertension, Pulmonary Arterial Hypertension, Pulmonary Circulation +9

Risk stratification in pulmonary arterial hypertension using Bayesian analysis

Manreet Kanwar, Mardi Gomberg‐Maitland, Marius M. Hoeper et al. · European Respiratory Journal · 2020 · 55 citations · Full text